Given the success of treating SLE with rituximab in many open studies, the failure of two recent randomized, placebo-controlled trials (EXPLORER and LUNAR) to show added values from rituximab over conventional therapy was quite unexpected [ 78, 79].
Although there has been interest in eschewing DCE because of its added cost, many studies have shown added value of DCE [ 20].
Accordingly, results showed added value when integrating big data analytics into the decision making process.
This is a frequently used test battery program in cognitive research, and has shown added value in criminological research (e.g. Cauffman et al. 2005).
Some limited studies have shown added value of functional MRI in recurrent endometrial and ovarian cancers.
Interestingly, some of these investigations have shown added value of functional imaging not from anatomic localization but simply from the degree to which the parameters are abnormal.
Multiple proteomic biomarkers have been described for a variety of diseases, and several biomarkers have shown added value over current disease-management approaches, based on validation studies (e.g. in chronic kidney disease [ 1– 3], reviewed in [ 4, 5]).
Among the four biomarkers, only galectin-3 showed added values on top of SOFA score, CRP, and WBC (Fig. 4).
